Atorvastatin

Atorvastatin has been studied in 368 papers since 2001: 75 trials and 100 observational studies in people, 85 in animals, 24 in cells, 48 reviews; 184 in the past year. It is an approved medicine. The newest paper, Nov 17, 2026: “Comparative Effects of Atorvastatin and Pravastatin on Endothelial Viability and DRP1-Associated Signaling Following Irradiation”.

InterventionStatinsApproved 1996

368 papers study it40 more mention it444 findingsUpdated

PubChemChEBIMeSH

46 new papers in 30 daysSee all 404 papers on atorvastatin

At a glance

Atorvastatin improves cognition in mice across independent labs, although a mouse finding shows no clear effect; a human trial reports increased telomerase activity in people with hypercholesterolemia. Some trials concern aging; across all uses, some ended over a year ago without posted results or a citing paper. Some papers declare company ties, and some trials have developer sponsors.

444 findings in 192 papers from 2001 to 2026, 30 of them since May 2026

Independent labs found the same change in cells, mice and people. 148 independent labs in 40 countries; 530 trials, 93 about aging, 250 with no results posted.

“a primary cardiovascular event had occurred in 297 participants (10.9 events per 1000 person-years) in the atorvastatin group and in 412 participants (15.5 events per 1000 person-years) in the placebo group”
Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older AdultsThe New England journal of medicine2026doi:10.1056/nejmoa2607314

21 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
  • 148 independent labs in 40 countries
  • 21 findings against
  • 530 trials, 93 about aging, 250 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 25 of 427 findings with company ties
  • 72 of 530 trials sponsored by its developers
  • Human trial74
  • Humans99
  • Animals83
  • Model organisms1
  • Cells24
  • In silico8

44 studies gave atorvastatin to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on cisplatin-induced ototoxicity41.38% of the case group versus 44.4% of the control group experienced ototoxicity

Randomized trial56 peoplePatients with solid tumors receiving cisplatin chemotherapyDrug design, development and therapy, Nov 7, 2026

up: Increases proteomic response140 significant proteins in G1 versus 68 in G2+G3; FDR q<0.05

up: Increases CALCA/CGRPFDR q=0.044

Randomized trial133 peopleConfirmed statin myalgia compared with nocebo and tolerant controlsAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Lowers the risk of cardiovascular diseaseHR 0.70, 95% CI 0.61–0.82, P<0.001

no change: Has no effect on disability-free survivalHR 0.94, 95% CI 0.84–1.05, P = 0.25

Randomized trial5.9 years9,971 peopleBoth74.7±4.5 yearsOlder adultsThe New England journal of medicine, Aug 29, 2026

down: Decreases endocan

down: Decreases endoglin

Treated cohortmedian 12 (IQR 8–12) weeks128 peoplewomenmedian age 60 years (IQR 56–64 years)Postmenopausal women aged up to 70 yearsBiomedicines, Aug 27, 2026

no change: Has no effect on frailty status

down: Decreases body weight

no change: Has no effect on myostatin

Randomized trial12 weeksPatient cohortsNarra X, Jul 13, 2026

What did studies of atorvastatin find?

283

Studies of atorvastatin measured 283 outcomes; the most studied are inflammation (16 studies), cognitive function (10) and LDL cholesterol (9).

Inflammation

downin humans6downin mice4downin rats4downin mouse cells1+1

16 studies
  1. Atorvastatin inhibits inflammation in humans (decompensated liver cirrhosis).

    “Inflammatory biomarkers demonstrated a marked response to atorvastatin therapy.”

    Human trialdecompensated liver cirrhosissix monthsn = 110

    Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial

    Scientific reports

  2. Atorvastatin inhibits inflammation in humans (decompensated cirrhosis) (P < 0.05).

    “These clinical improvements were mirrored by significant reductions in MDA, NF-κB, LPS, and zonulin levels (P < 0.05)”

    Human trialdecompensated cirrhosis20 mg/daysix monthsn = 100

    Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial

    Scientific reports

  3. Atorvastatin decreases inflammation in humans (combined with polyene phosphatidylcholine in MAFLD patients) (all P < 0.05).

    “inflammatory factors and liver injury index transforming growth factor-β (TGF-β) and nuclear transcription factor-κB (NF-κB) levels were significantly improved (all P < 0.05)”

    Human trialcombined with polyene phosphatidylcholine in MAFLD patientssix monthsn = 92

    Clinical efficacy and mechanism of polyene phosphatidylcholine combined with atorvastatin in treating metabolic associated fatty liver disease

    Pakistan journal of pharmaceutical sciences

  4. Atorvastatin decreases inflammation in humans (versus ezetimibe, on background PCSK9 inhibitor therapy).

    “statins provide greater improvements to EC health and anti-inflammatory effects, supporting their benefits beyond LDL-C reduction.”

    Human trialversus ezetimibe, on background PCSK9 inhibitor therapyendothelial cells1 month

    Direct Vascular Endothelial Assessment Highlights the Pleotropic Anti-Inflammatory Properties of Statin Therapy: Findings from the American Heart Association Cardiometabolic Health Strategically Focused Research Network

    AHA Scientific Sessions 2025 abstract

  5. Atorvastatin decreases inflammation in humans (hypertension).

    “serum inflammatory markers, including TNF-α, hs-CRP, and IL-6, were significantly lower in the experimental group than in the control group (all P < 0.05).”

    Human trialhypertension12 weeksn = 68

    Efficacy of atorvastatin calcium on clinical manifestations and serum inflammatory markers in elderly patients with hypertension

    American journal of translational research

  6. Atorvastatin decreases inflammation.

    “After treatment, reduced levels of IL-6, TNF-α, and hs-CRP were noted in the observation group versus those in the control group (all p < 0.05).”

    Human trial12 weeksn = 86

    Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway

    Diagnostic pathology

  7. Atorvastatin decreases inflammation in humans.

    “the available evidence supports the combined lipid-lowering and anti-inflammatory effects of atorvastatin across diverse patient populations”

    Review

    The Role and Status of Atorvastatin in the Cholesterol and Inflammation Dual-Target Era: A narrative review

    Frontiers in pharmacology

  8. Atorvastatin decreases inflammation in mice (female AS mouse models).

    “reduces inflammatory signaling, and enhances plaque stabilization in female AS mouse models.”

    Animalsfemale AS mouse modelsfemales

    A hierarchical theranostic nanoagent for multimodal imaging and targeted foam cell intervention in atherosclerosis

    Nature communications

  9. Atorvastatin decreases inflammation in rats (zoledronic acid-induced MRONJ).

    “It also reduced inflammation”

    Animalszoledronic acid-induced MRONJHPMC and graphene oxide hydrogel loaded with ATVjaw1.2%three weeksfemales

    Characterization and therapeutic effects of an atorvastatin graphene oxide hydrogel on medication induced osteonecrosis of the jaws in female rats

    Tissue & cell

  10. Atorvastatin inhibits inflammation in mice (myocardial infarction).

    “decreased levels of tumor necrosis factor-α, interleukin-6, and malondialdehyde”

    Animalsmyocardial infarction

    Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction

    Nanomedicine (London, England)

All 17

More on Inflammation

Cognitive function

upin mice4upin rats4upin humans1no changein humans1+1

10 studies
  1. Atorvastatin improves cognitive function in humans (β = 0.980, P < 0.001).

    “atorvastatin was an independent protective factor for cognitive recovery (β = 0.980, P < 0.001).”

    Human trial20 mg nightly6 monthsn = 67

    Atorvastatin accelerates hematoma absorption and ameliorates cognitive impairment in patients with chronic subdural hematoma complicated by cognitive dysfunction: a retrospective analysis

    Frontiers in pharmacology

  2. Atorvastatin showed no clear effect on cognitive function in humans (0.1 units (95% CI, -0.3 to 0.03)).

    “with no significant group differences (0.1 units; 95% CI, -0.3 to 0.03; P = .12)”

    Human trialwithout dementia and with hypertension, family history of dementia, and/or self-reported subjective cognitive decline24 monthsn = 480

    Effects of Exercise and Intensive Vascular Risk Reduction on Cognitive Function in Older Adults: A Randomized Clinical Trial

    JAMA neurology

  3. Atorvastatin improves cognitive function in TNP rats.

    “improved learning ability, preserved myelin structure, and restored MBP levels”

    Animalsin TNP rats10 mg/kg/day

    Hippocampal myelin damage contributes to cognitive impairment in a rat model of trigeminal neuropathic pain: Neuroprotective and anti-inflammatory effects of atorvastatin

    Neuroscience research

  4. Atorvastatin improves cognitive function in rats.

    “long-term atorvastatin intervention ameliorates cognitive decline in naturally aged rats”

    Animalsbrainlong-term

    Long-term atorvastatin improves cognitive function by modulating SIRT2-mediated dynamic transition of NFL lysine 272 crotonylation to ubiquitination in naturally aging rats

    Cell death discovery

  5. Atorvastatin improves cognitive function in rats (Aβ1−42-induced Alzheimer's disease model).

    “We confirmed that ATOR administration significantly attenuates the Aβ1−42-induced cognitive decline”

    AnimalsAβ1−42-induced Alzheimer's disease modelbrainmales

    HMGCR Inhibitor Restores Mitochondrial Dynamics by Regulating Signaling Cascades in a Rodent Alzheimer's Disease Model

    Molecular neurobiology

  6. Atorvastatin improves cognitive function in ApoE-/- mice.

    “Collectively, Atorvastatin mitigated memory deficits and brain monocyte infiltration in ApoE-/- mice.”

    Animalsin ApoE-/- miceoral10 mg/kg/day

    Atorvastatin mitigates memory deficits and brain monocyte infiltration in chronic hypercholesterolemia

    Aging

  7. Atorvastatin improves cognitive function in rats (AlCl3-induced model; alone and combined with magnesium l-threonate; radial arm maze).

    “At the end of the fourth week, administration of atorvastatin and atorvastatin with magnesium L-threonate resulted in a decreased average time taken to reach the correct arm”

    AnimalsAlCl3-induced model; alone and combined with magnesium l-threonate; radial arm mazefemalesn = 30

    Enhanced Neuroprotective Synergy of Atorvastatin and Magnesium L-Threonate in a Rat Model of Alzheimer's Disease Induced by Aluminum Chloride

    Cureus

  8. Atorvastatin improves cognitive function in hyperhomocysteinemic mice, tested by novel object recognition.

    “atorvastatin treatment in HHcy mice led to improved cognition on the novel object recognition task”

    Animalsin hyperhomocysteinemic mice, tested by novel object recognition14 weeks

    Atorvastatin rescues hyperhomocysteinemia-induced cognitive deficits and neuroinflammatory gene changes

    Journal of neuroinflammation

  9. Atorvastatin showed no clear effect on cognitive function in mice (high-fat diet-induced cognition impairment).

    “However, these effects were not observed in the high-dose of Ator.”

    Animalshigh-fat diet-induced cognition impairment80 mg7 monthsmales

    Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation

    Neurochemical research

  10. Atorvastatin improves cognitive function in mice (high-fat diet-induced cognition impairment).

    “Our results showed that moderate- and low-dose of Ator can significantly attenuate cognition impairment induced by HFD”

    Animalshigh-fat diet-induced cognition impairment20 or 40 mg7 monthsmales

    Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation

    Neurochemical research

All 11

LDL cholesterol

downin humans9−41%

9 studies
  1. Atorvastatin decreases LDL cholesterol in humans (acute myocardial infarction) (43 ± 16 mg/dL vs 48 ± 14 mg/dL, p = 0.046).

    “Group A had lower mean LDL-C (43 ± 16 mg/dL vs 48 ± 14 mg/dL; p = 0.046)”

    Human trialacute myocardial infarctionatorvastatin 80 mg or rosuvastatin 40 mg plus ezetimibe 10 mg vs atorvastatin 40 mg or rosuvastatin 20 mg plus ezetimibe 10 mg30 daysn = 220

    High-intensity versus very-high-intensity statin, both on top of ezetimibe, in acute myocardial infarction: A pragmatic randomized study

    International journal of cardiology

  2. Atorvastatin decreases LDL cholesterol in humans (compared with pravastatin 40 mg/day) (-53% vs -28% median percent change (pravastatin)).

    “The median percent lowering (interquartile range) in LDL-C was significantly greater with ATV than PRV [-53 (-69 to 20)% vs -28 (-55 to 74)%, p < 0.001]”

    Human trialcompared with pravastatin 40 mg/day80 mg/day12 monthsfemalesn = 420

    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial

    Atherosclerosis

  3. Atorvastatin decreases LDL cholesterol in humans (-40.0 mg/dL (95%CI -69.910 to -10.1)).

    “Atorvastatin reduced LDL-c by 40.0 mg/dL (95%CI: -69.910--10.1; p = 0.010)”

    Human trial80 mgfemales

    The Interplay of Sirtuin-1, LDL-Cholesterol, and HDL Function: A Randomized Controlled Trial Comparing the Effects of Energy Restriction and Atorvastatin on Women with Premature Coronary Artery Disease

    Antioxidants (Basel, Switzerland)

  4. Atorvastatin decreases LDL cholesterol in humans.

    “a fast decline of LDL-cholesterol, after intake of atorvastatin”

    Human trial

    Case of hepatotoxicity of atorvastatin: the search for a possible etiology

    Tijdschrift voor gerontologie en geriatrie

  5. Atorvastatin decreases LDL cholesterol in humans.

    “Atorvastatin administration resulted in a significant decrease in blood levels of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, vitamin E, and CoQ10 (P < .05)”

    Human trial10 mg/d5 monthsn = 19

    Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients

    Nutrition research (New York, N.Y.)

  6. Atorvastatin decreases LDL cholesterol in humans (heterozygous familial hypercholesterolemia) (-40.7%).

    “Pitavastatin and atorvastatin caused significant and almost comparable reductions in serum levels of total cholesterol (-35.4 vs. -33.8%), low-density lipoprotein cholesterol (-42.8 vs. -40.7%)”

    Human trialheterozygous familial hypercholesterolemia20 mgn = 19

    Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study

    Clinical pharmacology and therapeutics

  7. Atorvastatin decreases LDL cholesterol in humans (CoQ10 and placebo arms) (43% decrease in CoQ10 group; 49% decrease in placebo group).

    “Serum LDL-C levels in the CoQ10 group decreased by 43%, while in the placebo group by 49%.”

    Human trialCoQ10 and placebo arms10mg/day16 weeks

    Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study

    Atherosclerosis

  8. Atorvastatin decreases LDL cholesterol in humans (chronic heart failure) (p<0.001).

    “Atorvastatin treatment lowered triglycerides, LDL-cholesterol and coenzyme Q(10) levels (all p<0.001)”

    Human trialchronic heart failure40 mg6 weeksn = 24

    Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure

    Atherosclerosis

  9. Atorvastatin decreases LDL cholesterol in humans.

    “Atorvastatin exhibits several notable features: a titratable dosing strategy that spans all risk categories, robust LDL-C lowering”

    Review

    The Role and Status of Atorvastatin in the Cholesterol and Inflammation Dual-Target Era: A narrative review

    Frontiers in pharmacology

More on LDL cholesterol

Oxidative stress and ROS signaling

downin mice5downin rats2upin C. albicans cells1upin O. niloticus1

9 studies
  1. Atorvastatin induces oxidative stress and ROS signaling in O. niloticus.

    “Lipid peroxidation increased only at 0.2 and 0.5 mg/kg of ATV, suggesting oxidative damage at these concentrations.”

    Animals0.2 and 0.5 mg/kg45 days

    Evaluation of Toxicity and Oxidative Stress Following Chronic Exposure to Lipid-Lowering Drug Atorvastatin Using Nile Tilapia

    Research SquarePreprint

  2. Atorvastatin increases oxidative stress and ROS signaling in C. albicans cells (Strain MTCC 854) (18-fold increase).

    “ROS generation assay revealed an 18-fold increase in oxidative stress with Atorvastatin, while Simvastatin showed only a 4-fold increase.”

    CellsStrain MTCC 854

    Repurposing statins as potential antifungal agents for Candida albicans: in-vitro and in-silico approach

    Future microbiology

  3. Atorvastatin inhibits oxidative stress and ROS signaling in mice (myocardial infarction).

    “increased the enzyme activity of superoxide dismutase”

    Animalsmyocardial infarction

    Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction

    Nanomedicine (London, England)

  4. Atorvastatin decreases oxidative stress and ROS signaling in mice (PM2.5 exposure).

    “Both drugs ameliorated reactive oxygen species (ROS) formation”

    AnimalsPM2.5 exposurevasculature20 mg/kg/d3 daysmales

    Angiotensin-Converting Enzyme (ACE) Inhibitors and Statins Mitigate Negative Cardiovascular and Pulmonary Effects of Particulate Matter in a Mouse Exposure Model

    Antioxidants (Basel, Switzerland)

  5. Atorvastatin decreases oxidative stress and ROS signaling in rats (aged rats).

    “as evidenced by increased levels of Nrf-2, GSH, and SOD, along with a reduction in MDA levels”

    Animalsaged ratscerebral cortex20 mg/kg30 days

    Atorvastatin ameliorates cerebral cortical pathological and cognitive alterations in aged rats: Histological & immunohistochemical study

    Tissue & cell

  6. Atorvastatin decreases oxidative stress and ROS signaling in rats (AlCl3-induced model; alone and combined with magnesium l-threonate; brain).

    “and suppressed oxidative stress, as indicated by a decrease in nitric oxide (NO) levels and an increase in superoxide dismutase (SOD) and catalase levels.”

    AnimalsAlCl3-induced model; alone and combined with magnesium l-threonate; brainbrainfemalesn = 30

    Enhanced Neuroprotective Synergy of Atorvastatin and Magnesium L-Threonate in a Rat Model of Alzheimer's Disease Induced by Aluminum Chloride

    Cureus

  7. Atorvastatin prevents oxidative stress and ROS signaling in mice (age-related hearing loss).

    “These processes of ARHL were significantly prevented with administration of AS.”

    Animalsage-related hearing loss6 consecutive months

    Effect of statin on age-related hearing loss via drug repurposing

    Biochimica et biophysica acta. Molecular cell research

  8. Atorvastatin decreases oxidative stress and ROS signaling in mice (chronic intermittent hypoxia).

    “Atorvastatin significantly reversed those effects (p < 0.05).”

    Animalschronic intermittent hypoxiacardiac tissue5 mg/kg6 weeks

    Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model

    Aging

  9. Atorvastatin decreases oxidative stress and ROS signaling in mice (high-fat diet-induced cognition impairment).

    “MDA was notably decreased, whereas the activity of SOD, CAT, and GSH-Px was increased.”

    Animalshigh-fat diet-induced cognition impairment20 or 40 mg7 monthsmales

    Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation

    Neurochemical research

More on Oxidative stress and ROS signaling

Apoptosis

upin human cells2downin mice2downin rats2no changein mice1+1

8 studies
  1. Atorvastatin decreases apoptosis in mice (doxorubicin cardiotoxicity).

    “In a murine model of DOX cardiotoxicity, atorvastatin preserved left ventricular systolic function, reduced myocardial apoptosis and fibrosis”

    Animalsdoxorubicin cardiotoxicitymyocardium

    Atorvastatin protects cardiomyocytes from doxorubicin toxicity by modulating YAP/TAZ signaling

    BMB reports

  2. Atorvastatin inhibits apoptosis in mice (myocardial infarction).

    “Ato@DSPE-PEG-CHP reduced infarct size, cell necrosis, inflammation, fibrosis, and apoptosis”

    Animalsmyocardial infarction

    Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction

    Nanomedicine (London, England)

  3. Atorvastatin induces apoptosis in lipopolysaccharide-stimulated HT-29 and Caco-2 cells.

    “Both pathways converge upon activation of executioner caspase-3 and an increase in Annexin V-defined apoptotic fractions”

    Cellsin lipopolysaccharide-stimulated HT-29 and Caco-2 cells

    Pharmacologic Modulation of the PAR-2-ERK Axis by Statins Converts Inflammatory Survival Signalling into Apoptosis in Colorectal Cancer Cells

    International journal of molecular sciences

  4. Atorvastatin induces apoptosis in two PCa cell lines.

    “Results of cell experiments also demonstrated that statins use could promote apoptosis of PCa cells.”

    Cellsin two PCa cell lines

    Association of genetically instrumented HMGCR inhibition with the therapeutic role of prostate cancer: a Mendelian randomization study and supporting in vitro experiments

    Frontiers in pharmacology

  5. Atorvastatin decreases apoptosis in rats (aged rats).

    “apoptosis was mitigated through the downregulation of Caspase-3”

    Animalsaged ratscerebral cortex20 mg/kg30 days

    Atorvastatin ameliorates cerebral cortical pathological and cognitive alterations in aged rats: Histological & immunohistochemical study

    Tissue & cell

  6. Atorvastatin decreases apoptosis in scar region of RE-AMI.

    “The scar region of RE-AMI of animals treated with IV-atorva at index event showed reduced cardiac inflammatory infiltrate, apoptosis and senescence activation”

    Animalsin scar region of RE-AMImyocardium

    Cardioprotection exerted by intravenous statin at index myocardial infarction event attenuates cardiac damage upon recurrent infarction

    Cardiovascular research

  7. Atorvastatin inhibits apoptosis in MI/R and H/R model.

    “atorvastatin treatment attenuated MI/R and H/R mediated inflammatory and heart injury markers, cell apoptosis and cell death”

    Animalsin MI/R and H/R model

    In vivo and in vitro impact of atorvastatin against myocardial ischaemia-reperfusion injury by upregulation of silent information regulator l and attenuation of endoplasmic reticulum stress-induced apoptosis

    Journal of drug targeting

  8. Atorvastatin showed no clear effect on apoptosis in mice (chronic intermittent hypoxia).

    “Atorvastatin had no effect on those changes (p > 0.05).”

    Animalschronic intermittent hypoxiacardiac tissue5 mg/kg6 weeks

    Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model

    Aging

More on Apoptosis

Cellular senescence

downin human cells3upin mice1downin pigs1downin rats1

6 studies
  1. Atorvastatin decreases cellular senescence in scar region of RE-AMI.

    “The scar region of RE-AMI of animals treated with IV-atorva at index event showed reduced cardiac inflammatory infiltrate, apoptosis and senescence activation”

    Animalsin scar region of RE-AMImyocardium

    Cardioprotection exerted by intravenous statin at index myocardial infarction event attenuates cardiac damage upon recurrent infarction

    Cardiovascular research

  2. Atorvastatin inhibits cellular senescence in human cells (caused by oxidative stress and 5-Fu).

    “Atorvastatincalcium (Ator) alleviated cellular senescence in human intestinal epithelial cells (HUVECs) and human umbilical vein endothelial cells (HIECs) caused by oxidative stress and 5-Fu.”

    Cellscaused by oxidative stress and 5-Fu

    Atorvastatin calcium alleviates 5-fluorouracil-induced intestinal damage by inhibiting cellular senescence and significantly enhances its antitumor efficacy

    International immunopharmacology

  3. Atorvastatin induces cellular senescence in mice.

    “as well as increased accumulation of the senescence-associated β-galactosidase (SA-β-gal) stain in adipose tissues”

    Animalsadipose tissue

    Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes Ferroptosis-Related Senescence in Adipose Tissue

    Nutrients

  4. Atorvastatin decreases cellular senescence in human cells (IH-mediated senescence-like phenotype in preadipocytes).

    “Intervention with aspirin, atorvastatin or renin-angiotensin system (RAS) inhibitors effectively attenuated IH-mediated senescence-like phenotype.”

    CellsIH-mediated senescence-like phenotype in preadipocyteswhite preadipocytes

    Chronic Intermittent Hypoxia Triggers a Senescence-like Phenotype in Human White Preadipocytes

    Scientific reports

  5. Atorvastatin decreases cellular senescence in human cells (Ang II-induced dysfunction).

    “endothelial senescence, which was delayed by Ator”

    CellsAng II-induced dysfunction

    Atorvastatin reverses the dysfunction of human umbilical vein endothelial cells induced by angiotensin II

    Experimental and therapeutic medicine

  6. Atorvastatin decreases cellular senescence in rats (high-fat diet-induced hyperlipidemia).

    “these phenomena were reversed by atorvastatin”

    Animalshigh-fat diet-induced hyperlipidemia

    Atorvastatin exerts inhibitory effect on endothelial senescence in hyperlipidemic rats through a mechanism involving down-regulation of miR-21-5p/203a-3p

    Mechanisms of ageing and development

More on Cellular senescence

Coenzyme Q10

downin humans4no changein humans1

5 studies
  1. Atorvastatin decreases coenzyme Q10 in humans.

    “Atorvastatin administration resulted in a significant decrease in blood levels of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, vitamin E, and CoQ10 (P < .05)”

    Human trial10 mg/d5 monthsn = 19

    Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients

    Nutrition research (New York, N.Y.)

  2. Atorvastatin decreases coenzyme Q10 in humans (-26.1%, P=0.0007).

    “plasma levels of CoQ10 were reduced by atorvastatin (-26.1%, P=0.0007)”

    Human trial20 mgn = 19

    Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study

    Clinical pharmacology and therapeutics

  3. Atorvastatin decreases coenzyme Q10 in humans after 3 months of atorvastatin therapy (0.43 +/- 0.23 to 0.16 +/- 0.10 microg/mL).

    “coenzyme Q10 (0.43 +/- 0.23 to 0.16 +/- 0.10 microg/mL) were all significantly reduced (all p<0.001)”

    Human trialafter 3 months of atorvastatin therapy10 mg/day3 monthsn = 26

    Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia

    BioFactors (Oxford, England)

  4. Atorvastatin decreases coenzyme Q10 in humans (chronic heart failure) (p<0.001).

    “Atorvastatin treatment lowered triglycerides, LDL-cholesterol and coenzyme Q(10) levels (all p<0.001)”

    Human trialchronic heart failure40 mg6 weeksn = 24

    Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure

    Atherosclerosis

  5. Atorvastatin showed no clear effect on coenzyme Q10 in humans (0.65 +/- 0.22 vs 0.6 +/- 0.12 microg/mL, P >.05).

    “There was no difference in CoQ10 levels from baseline to post-drug therapy for either P or A”

    Human trial10 mg4 weeks

    The effect of pravastatin and atorvastatin on coenzyme Q10

    American heart journal

More on Coenzyme Q10

Total cholesterol

downin humans2no changein humans1no changein O. cuniculus1

4 studies
  1. Atorvastatin showed no clear effect on total cholesterol in humans (compared with placebo, fully adjusted model).

    “atorvastatin did not improve frailty status, frailty-related components, total cholesterol, or serum myostatin levels compared with placebo in PLHIV receiving ART”

    Human trialcompared with placebo, fully adjusted model40 mg once daily12 weeks

    Effect of atorvastatin on frailty-related outcomes, body composition and biochemical markers in people living with HIV: A randomized, double-blind, placebo-controlled clinical trial

    Narra X

  2. Atorvastatin decreases total cholesterol in humans (early menopausal women with hypercholesterolemia; compared to baseline).

    “both Xuezhikang and atorvastatin significantly reduced the levels of total cholesterol, triglycerides, low density cholesterol compared to baseline (all P<0.01).”

    Human trialearly menopausal women with hypercholesterolemia; compared to baselineserum10 mg/d8 weeksfemales

    Effect of "Natural Polypill", Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia

    Chinese journal of integrative medicine

  3. Atorvastatin decreases total cholesterol in humans (decreased significantly).

    “Serum total cholesterol and LDL-cholesterol levels decreased significantly.”

    Human trial10 mg/day8 weeksn = 14

    Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients

    Journal of atherosclerosis and thrombosis

  4. Atorvastatin showed no clear effect on total cholesterol in WHHL rabbits.

    “No effect on total cholesterol, triglycerides, HDL or LDL was observed.”

    Animalsin WHHL rabbits2.5 mg/kg/daymalesn = 34

    A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits

    Atherosclerosis

More on Total cholesterol

Hematoma volume

downin humans2no changein humans1downin rats1

4 studies
  1. Atorvastatin decreases hematoma volume in humans.

    “Atorvastatin significantly reduced hematoma volume and elevated MoCA scores at 1, 3 and 6 months”

    Human trial20 mg nightly6 monthsn = 67

    Atorvastatin accelerates hematoma absorption and ameliorates cognitive impairment in patients with chronic subdural hematoma complicated by cognitive dysfunction: a retrospective analysis

    Frontiers in pharmacology

  2. Atorvastatin showed no clear effect on hematoma volume in humans (postoperative chronic subdural hematoma) (p=0.979).

    “The hematoma volume was similar between the 2 groups (p=0.979).”

    Human trialpostoperative chronic subdural hematomaoralat least 1 weekn = 49

    Effects of postoperative atorvastatin use in elderly patients with chronic subdural hematoma

    European review for medical and pharmacological sciences

  3. Atorvastatin decreases hematoma volume in humans (Chronic subdural hematoma; uncontrolled before-and-after comparison) (48.70±20.38 ml to 16.64±14.28 ml).

    “the reduction in hematoma volume from 48.70±20.38 ml to 16.64±14.28 ml (paired-sample t-test, p<0.01) within the first month of the treatment.”

    Human trialChronic subdural hematoma; uncontrolled before-and-after comparison20 mg/day1 monthn = 23

    Effects of atorvastatin on chronic subdural hematoma: a preliminary report from three medical centers

    Journal of the neurological sciences

  4. Atorvastatin decreases hematoma volume in rats with CSDH, compared with saline (decreased on day 14 and day 21 (P<0.05)).

    “atorvastatin treatment accelerated the absorption of CSDH as indicated by decreased hematoma volume in T2WI MRI data on 14th and 21st day after CSDH”

    Animalsin rats with CSDH, compared with salineday 14 and day 21

    Role of Regulatory T cells in Atorvastatin Induced Absorption of Chronic Subdural Hematoma in Rats

    Aging and disease

Low-density lipoprotein cholesterol

downin humans4−47%

4 studies
  1. Atorvastatin decreases low-density lipoprotein cholesterol in humans (overweight and obese middle-aged and older adults) (-47%).

    “the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149+/-6 to 80+/-8 mg/dL)”

    Human trialoverweight and obese middle-aged and older adults80 mg/d12 weeksn = 16

    Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults

    Hypertension (Dallas, Tex. : 1979)

  2. Atorvastatin decreases low-density lipoprotein cholesterol in humans after 3 months of atorvastatin therapy.

    “coenzyme Q10 (0.43 +/- 0.23 to 0.16 +/- 0.10 microg/mL) were all significantly reduced (all p<0.001)”

    Human trialafter 3 months of atorvastatin therapy10 mg/day3 monthsn = 26

    Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia

    BioFactors (Oxford, England)

  3. Atorvastatin decreases low-density lipoprotein cholesterol in humans (102 +/- 21 vs 52 +/- 14 mg/dL, P <.01).

    “There was a significant difference in low-density lipoprotein (LDL) levels from baseline to post-drug therapy for both P and A”

    Human trial10 mg4 weeks

    The effect of pravastatin and atorvastatin on coenzyme Q10

    American heart journal

  4. Atorvastatin decreases low-density lipoprotein cholesterol in patients with lung diseases (WMD -21.48 mg/dL, 95% CI -30.82 to -12.14).

    “LDL cholesterol (WMD: - 21.48 mg/dL; 95% CI - 30.82 to - 12.14)”

    Reviewin patients with lung diseasesn = 1,344

    Effects of atorvastatin on inflammatory markers, lipid profile, liver enzymes, and pulmonary function in patients with lung diseases: a systematic review and meta-analysis of randomized controlled trials

    European journal of medical research

More on Low-density lipoprotein cholesterol

C-reactive protein

downin humans4−6% decrease

4 studies
  1. Atorvastatin decreases C-reactive protein in humans (on background PCSK9 inhibitor therapy) (6% decrease).

    “After 1 month of LLT, LDL-C and hsCRP decreased by 80% and 6%, respectively, in the statin group (P<0.05 for each).”

    Human trialon background PCSK9 inhibitor therapy80 mg1 month

    Direct Vascular Endothelial Assessment Highlights the Pleotropic Anti-Inflammatory Properties of Statin Therapy: Findings from the American Heart Association Cardiometabolic Health Strategically Focused Research Network

    AHA Scientific Sessions 2025 abstract

  2. Atorvastatin decreases C-reactive protein in humans (very elderly patients with type 2 diabetes).

    “Atorvastatin significantly reduced homocysteine and C-reactive protein”

    Human trialvery elderly patients with type 2 diabetes

    Characteristics of carotid atherosclerosis in elderly patients with type 2 diabetes at different disease course, and the intervention by statins in very elderly patients

    Journal of diabetes investigation

  3. Atorvastatin decreases C-reactive protein in humans (atherosclerotic subjects, 12-week treatment).

    “The TBR as well as high-sensitivity C-reactive protein (hsCRP), E-selectin, MMP-9, monocyte chemotactic protein 1, FABP4 and follistatin values were reduced significantly after the 12-week atorvastatin treatment.”

    Human trialatherosclerotic subjects, 12-week treatment40 mg/day12 weeksn = 43

    The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers

    European journal of nuclear medicine and molecular imaging

  4. Atorvastatin decreases C-reactive protein in humans (overweight and obese middle-aged and older adults) (-42%).

    “a 42% reduction in high-sensitivity C-reactive protein (3.6+/-0.8 to 2.1+/-0.5 mg/L; both P<0.05).”

    Human trialoverweight and obese middle-aged and older adults80 mg/d12 weeksn = 16

    Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults

    Hypertension (Dallas, Tex. : 1979)

More on C-reactive protein

Mortality

no changein humans2upin O. niloticus1

3 studies
  1. Atorvastatin showed no clear effect on mortality in humans (1.9% (2/107) vs 4.1% (5/123)).

    “After 30 days, the all-cause mortality rate in the Ato group was 1.9% (2/107), whereas it was 4.1% (5/123) in the placebo control group, with no statistically significant difference (p =0.454, ).”

    Human trial30 daysn = 230

    Effects of Atorvastatin Therapy on Postoperative Delirium After Malignant Tumor Surgeries in Older Adults

    Neuropsychiatric disease and treatment

  2. Atorvastatin showed no clear effect on mortality in humans following surgery for malignant tumors.

    “30-day all-cause mortality did not vary significantly between the two groups.”

    Human trialfollowing surgery for malignant tumors40mg/day30-day

    Effects of Atorvastatin Therapy on Postoperative Delirium After Malignant Tumor Surgeries in Older Adults

    Neuropsychiatric disease and treatment

  3. Atorvastatin was not clearly linked with mortality in humans (compared with moderate-intensity statin users, before and after propensity score matching).

    “revealed no significant difference in ischaemic CCEs or all-cause mortality between the moderate-intensity statin users and 10 mg atorvastatin users”

    Humanscompared with moderate-intensity statin users, before and after propensity score matching10 mgn = 4,689

    Differences in preventing new-onset cardiovascular events with statin therapy in seniors aged 75 years and over: A cohort study in the South Korean National Health Insurance Database

    Basic & clinical pharmacology & toxicology

  4. Atorvastatin increases mortality in O. niloticus.

    “The findings of this study revealed dose-dependent mortality and alterations in morphological and behavioural patterns in fish exposed to high ATV concentrations.”

    Animals45 days

    Evaluation of Toxicity and Oxidative Stress Following Chronic Exposure to Lipid-Lowering Drug Atorvastatin Using Nile Tilapia

    Research SquarePreprint

LDL-C

downin humans3−80% decrease

3 studies
  1. Atorvastatin decreases LDL-C in humans (on background PCSK9 inhibitor therapy) (80% decrease).

    “After 1 month of LLT, LDL-C and hsCRP decreased by 80% and 6%, respectively, in the statin group (P<0.05 for each).”

    Human trialon background PCSK9 inhibitor therapy80 mg1 month

    Direct Vascular Endothelial Assessment Highlights the Pleotropic Anti-Inflammatory Properties of Statin Therapy: Findings from the American Heart Association Cardiometabolic Health Strategically Focused Research Network

    AHA Scientific Sessions 2025 abstract

  2. Atorvastatin decreases LDL-C in humans (-40 mg/dL).

    “Atorvastatin treatment reduced LDL-c by 40 mg/dL (β = −40.045; CI95% = −69.949–−10.140; p = 0.010).”

    Human trial60-dayfemalesn = 39

    The Interplay of Sirtuin-1, LDL-Cholesterol, and HDL Function: A Randomized Controlled Trial Comparing the Effects of Energy Restriction and Atorvastatin on Women with Premature Coronary Artery Disease

    Antioxidants (Basel, Switzerland)

  3. Atorvastatin is linked with lower LDL-C in humans (dyslipidemia) (-54.55%).

    “In 55 patients who completed follow-up, a decrease in LDL-C, total cholesterol, triglycerides, and ApoE was 54.55%, 40.60%, 53.1%, and 40.46%, respectively.”

    Humansdyslipidemia12-weekn = 55

    Association of polymorphisms of ApoE, ApoA1, PCSK9 with LDL-C modification following Atorvastatin therapy in dyslipidemic patients

    Research SquarePreprint

More on LDL-C

Rhabdomyolysis

upin humans3

3 studies
  1. Atorvastatin induces rhabdomyolysis in humans.

    “The cause for myopathy, rhabdomyolysis, and liver injury was ascertained to be Atorvastatin”

    Human trialfemales

    A Case Report of Statin-induced Myopathy, Rhabdomyolysis and Liver Injury (SILI): A Rare but Potentially Life-threatening Adverse Effect

    Euroasian journal of hepato-gastroenterology

  2. Atorvastatin induces rhabdomyolysis in humans (double prescribed dose of atorvastatin).

    “She was admitted to the hospital where she was found to have rhabdomyolysis.”

    Human trialdouble prescribed dose of atorvastatinfemales

    An Ounce of Prevention, a Pound of Complications: A Case of Statin-Induced Necrotizing Myopathy in a Frail Elderly Patient

    Geriatrics (Basel, Switzerland)

  3. Atorvastatin is linked with higher rhabdomyolysis in humans (single case; patient prescribed 80 mg daily after NSTEMI) (serum creatine kinase 18 723 U/L).

    “Prescribing high-intensity statins for patients with advanced age, such as this case, may increase the risk of rhabdomyolysis and other complications.”

    Humanssingle case; patient prescribed 80 mg daily after NSTEMI80 mg dailymales

    High-Intensity Atorvastatin-Induced Rhabdomyolysis in an Elderly Patient With NSTEMI: A Case Report and Review of the Literature

    Journal of pharmacy practice

More on Rhabdomyolysis

IL-6

no changein humans1upin humans1

2 studies
  1. Atorvastatin increases IL-6 in humans.

    “This positive atorvastatin effect on TA was associated with a statistically significant increase in IL-6 and a marginally significant decrease in blood urea.”

    Human trial12 months

    Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases

    Frontiers in pharmacology

  2. Atorvastatin showed no clear effect on IL-6 in humans (MD −0.82; 95% CI −3.02 to 1.38; p = 0.46).

    “No overall between-group differences were observed for IL-6 (n = 484; MD –0.82; 95% CI –3.02 to 1.38; p = 0.46)”

    ReviewComparison with rosuvastatin; adiponectin and TNF-α also showed no overall between-group differencesn = 484

    Comparative Effects of Atorvastatin and Rosuvastatin on Randomized Head-to-Head Trials: A Systematic Review and Meta-Analysis of Inflammatory Biomarker Changes

    AHA Scientific Sessions 2026 abstract

More on IL-6

All 283

What is atorvastatin linked with?

50

Studies link atorvastatin with 50 measures, among them cardiovascular disease, type 2 diabetes and postoperative delirium.

Cardiovascular disease

downin humans2HR 0.7

2 studies
  1. Atorvastatin lowers the risk of cardiovascular disease in humans (without clinical cardiovascular disease) (HR 0.70, 95% CI 0.61–0.82, P<0.001).

    “a primary cardiovascular event had occurred in 297 participants (10.9 events per 1000 person-years) in the atorvastatin group and in 412 participants (15.5 events per 1000 person-years) in the placebo group”

    Human trialwithout clinical cardiovascular disease40 mg once daily5.9 yearsn = 9,971

    Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults

    The New England journal of medicine

  2. Atorvastatin lowers the risk of cardiovascular disease in humans (elderly type 2 diabetes) (-3.65% (95% CI: -10.29%, 4.38%)).

    “total effect (six-year cardiovascular disease risk difference) estimated by standard plug-in g-formula of -3.65% (95% confidence interval: -10.29%, 4.38%)”

    Human trialelderly type 2 diabetes6 years

    Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin's effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics

    Statistical methods in medical research

More on Cardiovascular disease

Type 2 diabetes

upin humans2

2 studies
  1. Atorvastatin raises the risk of type 2 diabetes in humans (compared to agents such as pravastatin or pitavastatin).

    “High-intensity statins like atorvastatin and rosuvastatin carry a greater risk compared to agents such as pravastatin or pitavastatin.”

    Reviewcompared to agents such as pravastatin or pitavastatin

    Statin Induced New-onset Diabetes Mellitus - A Narrative Review

    Journal of community hospital internal medicine perspectives

  2. Atorvastatin raises the risk of type 2 diabetes in humans (dose- and susceptibility-dependent).

    “small dose- and susceptibility-dependent increase in new-onset diabetes”

    Reviewdose- and susceptibility-dependent

    Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management

    Cardiovascular therapeutics

More on Type 2 diabetes

Postoperative delirium

downin humans1

1 study
  1. Atorvastatin lowers the risk of postoperative delirium in humans.

    “As opposed to the Ato group, the placebo group exhibited a remarkably greater delirium occurrence rate, with a significant difference (p =0.003).”

    Human trial30 daysn = 230

    Effects of Atorvastatin Therapy on Postoperative Delirium After Malignant Tumor Surgeries in Older Adults

    Neuropsychiatric disease and treatment

  2. Atorvastatin lowers the risk of postoperative delirium in humans following surgery for malignant tumors.

    “The occurrence of delirium in the Ato group was remarkably reduced unlike the case in the placebo group.”

    Human trialfollowing surgery for malignant tumors40mg/day

    Effects of Atorvastatin Therapy on Postoperative Delirium After Malignant Tumor Surgeries in Older Adults

    Neuropsychiatric disease and treatment

More on Postoperative delirium

Cardiovascular events

downin humans1

1 study
  1. Atorvastatin lowers the risk of cardiovascular events in humans.

    “Multiple large trials have shown that atorvastatin achieves concurrent control of lipids and inflammation, accompanied by reductions in cardiovascular events.”

    Review

    The Role and Status of Atorvastatin in the Cholesterol and Inflammation Dual-Target Era: A narrative review

    Frontiers in pharmacology

Liver stiffness

downin humans1

1 study
  1. Atorvastatin is associated with liver stiffness in humans (type 2 diabetes mellitus; compared with no statin) (−0.42 kPa versus −0.02 kPa in the no-statin group).

    “both atorvastatin treatment groups remained significantly associated with lower six-month UACR and liver stiffness compared with the no-statin group”

    Humanstype 2 diabetes mellitus; compared with no statinliver10–20 mg/daysix monthsn = 205

    Treatment-Intensity Associations of Atorvastatin Therapy with Albuminuria and Liver Stiffness in Patients with Type 2 Diabetes and Hyperlipidemia: The ALI-STAR Study

    Medicina (Kaunas, Lithuania)

Urinary albumin-to-creatinine ratio

downin humans1

1 study
  1. Atorvastatin is associated with urinary albumin-to-creatinine ratio in humans (type 2 diabetes mellitus; compared with no statin) (−27.68 mg/g versus +8.64 mg/g in the no-statin group).

    “both atorvastatin treatment groups remained significantly associated with lower six-month UACR and liver stiffness compared with the no-statin group”

    Humanstype 2 diabetes mellitus; compared with no statin10–20 mg/daysix monthsn = 205

    Treatment-Intensity Associations of Atorvastatin Therapy with Albuminuria and Liver Stiffness in Patients with Type 2 Diabetes and Hyperlipidemia: The ALI-STAR Study

    Medicina (Kaunas, Lithuania)

More on Urinary albumin-to-creatinine ratio

Cardiovascular and cerebrovascular events

downin humans1

1 study
  1. Atorvastatin lowers the risk of cardiovascular and cerebrovascular events in humans (patients with carotid plaque; compared with no statin therapy) (22 events among 234 statin-treated patients versus 36 among 202 controls; log-rank P=0.0107).

    “22 events occurred among 234 patients in the statin group and 36 among 202 patients in the control group”

    Human trialpatients with carotid plaque; compared with no statin therapy20 mg dailyextended follow-up beyond 24 months through 2025

    Effect of atorvastatin on carotid plaque progression-a prospective study

    Frontiers in cardiovascular medicine

New-onset type 2 diabetes mellitus

downin humans1RR 0.94

1 study
  1. Atorvastatin is associated with new-onset type 2 diabetes mellitus in humans (stable coronary artery disease; propensity score-matched cohorts) (12.1% versus 12.8%; RR 0.94, 95% CI 0.92–0.96; HR 1.02, 95% CI 1.00–1.05; log-rank p=0.053).

    “Atorvastatin 40 mg was associated with modestly lower rates of both incident HF and new-onset T2DM compared to 80 mg.”

    Humansstable coronary artery disease; propensity score-matched cohorts40 mg versus 80 mg71% males

    Heart Failure and Diabetogenic Risk with Atorvastatin 40 mg versus 80 mg in Stable CAD: A Large-Scale Real-World Evidence Study

    AHA Scientific Sessions 2026 abstract

More on New-onset type 2 diabetes mellitus

Incident heart failure

downin humans1RR 0.95

1 study
  1. Atorvastatin is associated with incident heart failure in humans (stable coronary artery disease; propensity score-matched cohorts) (19.2% versus 20.3%; RR 0.95, 95% CI 0.93–0.96; HR 1.02, 95% CI 1.01–1.04).

    “Atorvastatin 40 mg was associated with modestly lower rates of both incident HF and new-onset T2DM compared to 80 mg.”

    Humansstable coronary artery disease; propensity score-matched cohorts40 mg versus 80 mg71% males

    Heart Failure and Diabetogenic Risk with Atorvastatin 40 mg versus 80 mg in Stable CAD: A Large-Scale Real-World Evidence Study

    AHA Scientific Sessions 2026 abstract

More on Incident heart failure

Circulating protein abundance

mixedin humans1

1 study
  1. Atorvastatin is associated with circulating protein abundance in humans (statin-intolerant patients; placebo-controlled crossover) (243/1,037 proteins (23.4%): 140 upregulated, 103 downregulated; 57 significant after adjustment: 8 upregulated, 49 downregulated).

    “atorvastatin significantly affected 243 out of 1,037 proteins (23.4%) in the unadjusted model (FDR q<0.05; 140 upregulated, 103 downregulated).”

    Human trialstatin-intolerant patients; placebo-controlled crossoverplasma20 mg54% femalesn = 133

    Atorvastatin Broadly Alters the Circulating Proteome in Statin-Intolerant Patients: A Proteomic Substudy of the GAUSS-3 Randomized Clinical Trial

    AHA Scientific Sessions 2026 abstract

More on Circulating protein abundance

Sinus arrest

upin humans1

1 study
  1. Atorvastatin is associated with sinus arrest in humans following high-dose exposure.

    “On admission, electrocardiography showed sinus arrest with a ventricular escape rhythm, accompanied by acute hepatic and renal dysfunction, electrolyte abnormalities, coagulation abnormalities, and elevated inflammatory markers.”

    Human trialfollowing high-dose exposure80 mg dailytwo weeksmalesn = 1

    Atorvastatin-Associated Severe Bradyarrhythmia Following Multiorgan Dysfunction: A Case Report

    Clinical case reports

More on Sinus arrest

Contrast-induced acute kidney injury

downin humans1RR 1.658

1 study
  1. Atorvastatin lowers the risk of contrast-induced acute kidney injury in humans (undergoing elective coronary angiography) (12.5% vs 32.5%, RR 1.658, 95% CI 1.050-2.433).

    “The incidence of CI-AKI was significantly lower in the high-dose statin group compared with the control group (risk ratio = 1.658; 95% CI 1.050-2.433).”

    Human trialundergoing elective coronary angiographyoral80 mg24 h before angiographyn = 80

    Preventing Contrast-Induced Acute Kidney Injury in Egyptian Patients Undergoing Coronary Angiography: A Randomized Controlled Trial

    Clinical drug investigation

More on Contrast-induced acute kidney injury

Pulmonary infection

downin humans1

1 study
  1. Atorvastatin lowers the risk of pulmonary infection in humans.

    “The incidence of pulmonary infection and bedsore in the Ato group was remarkably diminished as opposed to that in the placebo group (p<0.05, ).”

    Human trial30 daysn = 230

    Effects of Atorvastatin Therapy on Postoperative Delirium After Malignant Tumor Surgeries in Older Adults

    Neuropsychiatric disease and treatment

More on Pulmonary infection

Stroke

downin humans1HR 0.9

1 study
  1. Atorvastatin lowers the risk of stroke in humans (recent stroke or TIA) (HR 0.90, 0.73-1.11, p = 0.33).

    “and by 10% in elderly subjects (HR 0.90, 0.73-1.11, p = 0.33).”

    Human trialrecent stroke or TIA

    Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack

    Neurology

More on Stroke

Coronary artery disease

downin humans1HR 0.68

1 study
  1. Atorvastatin lowers the risk of coronary artery disease in humans (recent stroke or TIA) (HR 0.68, p = 0.035).

    “major coronary events (HR 0.68, p = 0.035), any coronary heart disease event (HR 0.61, p = 0.0006), and revascularization procedures (HR 0.55, p = 0.0005) was reduced in the elderly group.”

    Human trialrecent stroke or TIA

    Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack

    Neurology

More on Coronary artery disease

All 50

Has atorvastatin been tested in people?

93 of 530 about aging

Yes: 75 trials and 100 observational studies in people have been published, and 521 trials are registered.

Approved

  • FDA Lipitor

    Dec 17, 1996Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia, Myocardial Infarction, Stroke, Coronary Heart Disease, Heterozygous Familial Hypercholesterolemia, dysbetalipoproteinemia, angina, Hyperlipidemia, primary hyperlipidemia, non-fatal stroke

  • FDA Atorvaliq

    Feb 1, 2023Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia, Myocardial Infarction, Stroke, Coronary Heart Disease, Heart Failure, Congestive, Heterozygous Familial Hypercholesterolemia, dysbetalipoproteinemia, angina, Hyperlipidemia, primary hyperlipidemia, non-fatal stroke

Repurposing

40 of 182

Every condition in trials

  • Hyperlipidemias

    Phase 4Results posted41 trials

  • Variant Angina Pectoris

    Phase 4Terminated3 trials

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors

    Phase 4Status unknown2 trials

  • Amyloid plaque

    Phase 4Status unknown1 trial

  • Aortic coarctation

    Phase 4Terminated1 trial

  • Post operative atrial fibrillation

    Phase 4Status unknown1 trial

All 37

Stopped

  • NCT02133534TerminatedHypercholesterolemia

    failure to enroll

  • NCT02740699TerminatedCardiovascular disease

    Principal Investigator resigned and closed program

  • NCT00355251TerminatedHIV infection

    On the basis of published results of SMART study, it has been observed that the results are worse in patients who have interrupted their treatments.

  • NCT03228238TerminatedVariant Angina Pectoris

    The study was terminated early due to slow recruitment and the Principal Investigator's retirement.

  • NCT00590135TerminatedAortic valve stenosis

    Poor Reducibility - primary endpoint measure not obtainable

  • NCT05331053TerminatedEndometriosis

    COVID halting human subjects research and preliminary data from this proposal were used to submit an NIH grant. The NIH grant was funded and 3 other protocols were launched.

All 16

Who is developing atorvastatin?

3 companies: Organon, Laboratorios Senosiain S.A. de C.V. and Shenzhen Salubris Pharmaceuticals.

Companies
  • OrganonPhase 4hypercholesterolemia, atherosclerosis
  • Laboratorios Senosiain S.A. de C.V.Phase 3reduction of cardiovascular risk in adult patients with mixed dyslipidemia
  • Shenzhen Salubris PharmaceuticalsPhase 2hypercholesterolemia and mixed dyslipidemia

Trial sponsors

Funding

1 grant since 2023

National Institute on Deafness and Other Communication Disorders$1.5M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Atorvastatin improves cognition in mice across independent labs, although another study shows no clear effect; human trials report lower LDL cholesterol but differ on coenzyme Q10 reductions. Of its registered trials, 99 concern aging; 260 across all uses ended over a year ago without posted results or citing papers. Some trials have developer sponsors, and some papers declare Pfizer ties.

  2. Summary rewritten as its findings changed.

    As it read before

    A human trial reports no improvement in disability-free survival with atorvastatin; independent labs find improved mouse cognition, while a human study finds no cognitive benefit. Independent labs also report lower human LDL cholesterol and C-reactive protein. 31 trials concern aging; 258 across all uses ended over a year ago without posted results or citing papers, and two of 54 papers declare company ties.

  3. Summary rewritten as its findings changed.

    As it read before

    In humans, atorvastatin reduces plasma endoglin and endocan in females, and a preoperative trial shows it lowers cardiac troponin without affecting major adverse cardiovascular events. Reviews describe a dose-dependent increase in type 2 diabetes risk.

  4. Summary written from the findings.

Latest

Dec 2025: 8Jan 2026: 38Feb 2026: 32Mar 2026: 31Apr 2026: 4May 2026: 4Jun 2026: 1Jul 2026: 12Aug 2026: 12Sep 2026: 8Oct 2026: 25Nov 2026: 22197 papers in 12 months

See all 404 papers on atorvastatin